Measuring The Impact Of Next Generation Sequencing (Ngs) Technique Implementation In Metastatic Colorectal Cancer (Mcrc) Drug Development Program

3598 Background: Molecular screening and biomarker enrichment strategies in mCRC trials may impact patient (pt)´s outcome. The introduction of NGS technologies in clinical investigation may enhance pt inclusion through the discovery of a wider set of mutations (mt) in oncogenes and tumor suppressor genes. Methods: From March/2012 to December/2014 411 pts with chemorefractory mCRC underwent genetic tumor profiling as part of the molecular enhancement strategy in our early drug development program. Base extension chemistry followed by mass detection (MassARRAY, Sequenom) (SQ) was used including 268 frequent hotspots in 25 oncogenes with a sensitivity of 10% of mutant alleles. Since June/2014, Amplicon sequencing (NGS) was implemented assessing mt in 59 oncogenes and tumor suppressors with a sensitivity of 3% mutant alleles. Results: From March/2012 to Jun/2014 324 pts were screened using SQ, 261 mt were detected: 0.80 mt per patient. A total of 117 pts (36%) resulted wild-type (wt) after the test. Frequency...